Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity
Marla C. Dubinsky, Michelle Mendiolaza, Becky L. Phan, et al.
Inflammatory Bowel Diseases (2022) Vol. 28, Iss. 9, pp. 1375-1385
Closed Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study
Ronen Stein, Dan Turner, Séamus Hussey, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 1
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases
W Kantasiripitak, Sebastian G. Wicha, Debby Thomas, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 6, pp. 896-908
Open Access | Times Cited: 21
Model-informed precision dosing: State of the art and future perspectives
Iris K. Minichmayr, Erwin Dreesen, Marco Centanni, et al.
Advanced Drug Delivery Reviews (2024) Vol. 215, pp. 115421-115421
Open Access | Times Cited: 10
Challenges in IBD Research 2024: Precision Medicine
Sana Syed, Brigid S. Boland, Lauren T Bourke, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S39-S54
Open Access | Times Cited: 9
Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
Namita Singh, Marla C. Dubinsky
Springer eBooks (2023), pp. 445-456
Closed Access | Times Cited: 16
Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease
Elizabeth Spencer, Suzannah Bergstein, Michael Dolinger, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 11, pp. 2057-2063
Closed Access | Times Cited: 16
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future
Karla Cameron, Anke L. Nguyen, David Gibson, et al.
Journal of Gastroenterology and Hepatology (2025)
Open Access
The role of immunogenicity in optimizing biological therapies for inflammatory bowel disease
Konika Sharma, Brad W. deSilva, Stephen B. Hanauer
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease
Abigail Samuels, Kei Irie, Tomoyuki Mizuno, et al.
Clinical and Translational Science (2025) Vol. 18, Iss. 2
Open Access
Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities – a Workshop Report
Sophie Shubow, Michele Gunsior, Amy S. Rosenberg, et al.
The AAPS Journal (2025) Vol. 27, Iss. 2
Closed Access
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, et al.
BMJ Open (2022) Vol. 12, Iss. 4, pp. e057656-e057656
Open Access | Times Cited: 25
Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics
Tina Deyhim, Adam S. Cheifetz, Konstantinos Papamichael
Journal of Clinical Medicine (2023) Vol. 12, Iss. 22, pp. 7132-7132
Open Access | Times Cited: 12
Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn’s disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA
Phillip Minar, Ruben J. Colman, Nanhua Zhang, et al.
BMJ Open (2024) Vol. 14, Iss. 3, pp. e077193-e077193
Open Access | Times Cited: 4
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
“Getting the Dose Right”—Revisiting the Topic With Focus on Biologic Agents
Diane R. Mould, Richard N. Upton
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 613-618
Closed Access | Times Cited: 3
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance
Ruben J. Colman, Tomoyuki Mizuno, Keizo Fukushima, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 5, pp. 524-539
Open Access | Times Cited: 16
Barriers to optimizing inflammatory bowel disease care in the United States
Elizabeth Spencer, Sadeea Abbasi, Maia Kayal
Therapeutic Advances in Gastroenterology (2023) Vol. 16, pp. 175628482311696-175628482311696
Open Access | Times Cited: 8
Therapeutic drug monitoring in inflammatory bowel disease: A practical approach
Devendra Desai
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 93-102
Closed Access | Times Cited: 2
Clinical utility of C‐reactive protein‐to‐albumin ratio in the management of patients with inflammatory bowel disease
Anke L. Nguyen, Claudia Brick, David Liu, et al.
JGH Open (2024) Vol. 8, Iss. 4
Open Access | Times Cited: 2
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
Ole Haagen Nielsen, Alexander Hammerhøj, Mark Ainsworth, et al.
Drugs (2024)
Closed Access | Times Cited: 2
Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease
Abigail Samuels, Kaitlin G. Whaley, Phillip Minar
Current Gastroenterology Reports (2023) Vol. 25, Iss. 11, pp. 323-332
Open Access | Times Cited: 7
Forecasted Infliximab Concentrations During Induction Predict Time to Remission and Sustained Disease Control of Inflammatory Bowel Disease
Séverine Vermeire, Marla C. Dubinsky, Shervin Rabizadeh, et al.
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 6, pp. 102374-102374
Closed Access | Times Cited: 2
Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring
Devendra Desai, Alpa J. Dherai, Anne S. Strik, et al.
The Journal of Clinical Pharmacology (2022) Vol. 63, Iss. 4, pp. 480-489
Open Access | Times Cited: 11
Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies
Eric Cheah, James Guoxian Huang
World Journal of Gastroenterology (2023) Vol. 29, Iss. 10, pp. 1539-1550
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top